Ranbaxy Labs. - OHM Laboratories to launch Valsartan Tablets - Receives
first-to-file FDA approval, with 180-day marketing ex
27/06/2014 09:40
Ranbaxy Laboratories Ltd has submitted to BSE a copy of Press Release titled “OHM Laboratories to launch Valsartan Tablets - Receives first-to-file FDA approval, with 180-day marketing exclusivity for generic version in the treatment of hypertension and heart failure" which has been issued by Ohm Laboratories Inc, a wholly owned subsidiary of the Company.
27/06/2014 09:40
Ranbaxy Laboratories Ltd has submitted to BSE a copy of Press Release titled “OHM Laboratories to launch Valsartan Tablets - Receives first-to-file FDA approval, with 180-day marketing exclusivity for generic version in the treatment of hypertension and heart failure" which has been issued by Ohm Laboratories Inc, a wholly owned subsidiary of the Company.
